Primary Purpose
| primary_purpose | Study_Count |
|---|---|
| Treatment | 538 |
| Supportive Care | 12 |
| Diagnostic | 11 |
| Prevention | 7 |
| Basic Science | 3 |
| Health Services Research | 1 |
| Other | 1 |
| NA | 1 |
Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
| Type | Study_count |
|---|---|
| Total_Studies | 615 |
| interventional | 574 |
| Observational | 37 |
| Registry | 4 |
```
| intervention_type | Study_Count |
|---|---|
| Drug | 308 |
| Drug|Other | 39 |
| Biological|Drug | 38 |
| Biological | 32 |
| Biological|Drug|Other | 28 |
| Drug|Procedure | 20 |
| Biological|Other | 11 |
| Biological|Drug|Procedure|Radiation | 8 |
| Drug|Other|Procedure|Radiation | 8 |
| Drug|placebo | 8 |
| Biological|Drug|Other|Procedure|Radiation | 6 |
| Drug|Procedure|Radiation | 6 |
| Biological|Drug|Other|Procedure | 5 |
| Procedure | 5 |
| Biological|Drug|Procedure | 4 |
| Drug|Radiation | 4 |
| Other | 4 |
| Radiation | 4 |
| Biological|Other|Procedure | 3 |
| Drug|Genetic|Other | 3 |
| Drug|Other|Procedure | 3 |
| Biological|Drug|Radiation | 2 |
| Biological|Radiation | 2 |
| Device | 2 |
| Dietary Supplement|Other | 2 |
| Other|Procedure | 2 |
| Procedure|Radiation | 2 |
| Behavioral | 1 |
| Behavioral|Drug | 1 |
| Behavioral|Other | 1 |
| Biological|Dietary Supplement|Drug|Other|placebo | 1 |
| Biological|Drug|Genetic|Other | 1 |
| Biological|Drug|Genetic|Other|Procedure | 1 |
| Biological|Drug|Other|Radiation | 1 |
| Biological|Procedure|Radiation | 1 |
| Combination Product | 1 |
| Drug|Genetic|Other|Procedure|Radiation | 1 |
| Drug|Genetic|Procedure|Radiation | 1 |
| Drug|Other|placebo | 1 |
| Drug|Other|placebo|Procedure | 1 |
| Drug|Other|Radiation | 1 |
| Drug|placebo|Procedure | 1 |
| Country | Study_Count |
|---|---|
| United States | 286 |
| China | 55 |
| France | 14 |
| NA | 13 |
| United Kingdom | 11 |
| Korea, Republic of | 10 |
| Italy | 9 |
| United States|Canada | 8 |
| Belgium|France | 7 |
| Spain | 7 |
| United States|United Kingdom | 7 |
| Germany | 6 |
| Canada | 5 |
| Japan | 4 |
| United States|Germany|Italy | 4 |
| United States|Italy | 4 |
| Australia | 3 |
| Singapore | 3 |
| Austria | 2 |
| Belgium|France|Switzerland | 2 |
| Denmark|Finland|Norway|Sweden | 2 |
| Italy|Switzerland | 2 |
| Netherlands | 2 |
| Russian Federation | 2 |
| United States|Australia | 2 |
| United States|Australia|Italy | 2 |
| United States|Denmark|Germany | 2 |
| United States|Spain | 2 |
| Algeria|Argentina|Belgium|Brazil|Bulgaria|Canada|Colombia|Finland|France|Greece|Ireland|Israel|Italy|Netherlands|Peru|Poland|Portugal|Russian Federation|Saudi Arabia|Serbia|South Africa|Spain|Thailand|Turkey|Ukraine|United Kingdom|Venezuela | 1 |
| Argentina|Brazil|Colombia|India|Indonesia|Iran, Islamic Republic of|Malaysia|Mexico|Paraguay|Philippines|Russian Federation|South Africa | 1 |
| Australia|Austria|Belgium|France|Israel|Poland|Portugal|Spain|Switzerland | 1 |
| Australia|Austria|Bosnia and Herzegovina|Brazil|Bulgaria|China|Croatia|Czech Republic|Estonia|Hong Kong|Israel|Latvia|Macedonia, The Former Yugoslav Republic of|Malaysia|Mexico|Peru|Romania|Russian Federation|Serbia|Slovakia|Slovenia|South Africa|Sweden|Taiwan|Thailand|Turkey | 1 |
| Australia|Belgium|Canada|Denmark|France|Germany|Italy|Korea, Republic of|Singapore|United Kingdom | 1 |
| Australia|United States|Belgium|Canada|China|Czechia|France|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Russian Federation|Spain|Switzerland|Taiwan|Turkey | 1 |
| Austria|France|Norway | 1 |
| Austria|Switzerland | 1 |
| Belgium | 1 |
| Belgium|Canada|United States|Australia|France|Germany|Italy|Netherlands|Singapore|Spain|Sweden|United Kingdom | 1 |
| Belgium|Italy|Spain | 1 |
| Bosnia and Herzegovina|Croatia|Georgia|Moldova, Republic of|Poland|Serbia|Ukraine | 1 |
| Bulgaria|Estonia|France|Hungary|Italy|Latvia|Poland|Russian Federation|Spain|Ukraine | 1 |
| Czech Republic | 1 |
| Czechia|Italy|Netherlands|United Kingdom | 1 |
| Denmark|Netherlands|Spain|United Kingdom | 1 |
| Denmark|Sweden | 1 |
| France|Belgium | 1 |
| France|Germany|Russian Federation | 1 |
| France|Italy|Netherlands | 1 |
| France|Italy|Poland|Taiwan|Ukraine|Germany|United States|Australia|Canada|United Kingdom | 1 |
| Hungary|Argentina|Australia|Austria|Brazil|Canada|Chile|Colombia|Croatia|Denmark|Dominican Republic|Egypt|El Salvador|Germany|Guatemala|Hong Kong|Indonesia|Italy|Korea, Republic of|Malaysia|Netherlands|New Zealand|Panama|Peru|Philippines|Portugal|Romania|Sweden|Taiwan|Thailand|Turkey|Vietnam | 1 |
| India | 1 |
| Israel | 1 |
| Italy|Poland|United Kingdom | 1 |
| Italy|United States|Czechia|Japan|Korea, Republic of|Singapore | 1 |
| Japan|Korea, Republic of | 1 |
| Japan|United States|Argentina|Austria|Belgium|China|Czech Republic|Denmark|Estonia|Finland|Germany|Greece|Hungary|India|Ireland|Israel|Korea, Republic of|Netherlands|Norway|Poland|Russian Federation|Singapore|Spain|Sweden|Thailand|United Kingdom | 1 |
| Kenya|Zimbabwe | 1 |
| Malawi | 1 |
| Mexico | 1 |
| Netherlands|Belgium | 1 |
| New Zealand | 1 |
| Poland | 1 |
| Sweden | 1 |
| Switzerland|United Kingdom | 1 |
| Taiwan | 1 |
| Thailand | 1 |
| Turkey|Ukraine|Brazil|United States|Argentina|Australia|Belgium|Canada|China|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Japan|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Brazil|Canada|China|Colombia|Czechia|Egypt|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|New Zealand|Norway|Peru|Poland|Russian Federation|Saudi Arabia|Singapore|Slovakia|Spain|Switzerland|Thailand|Turkey|Venezuela | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Brazil|Canada|China|Czechia|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Bulgaria|Canada|France|Germany|Greece|Hungary|India|Israel|Italy|Netherlands|New Zealand|Poland|Serbia|Spain|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Canada|France|Germany|Israel|Italy|Netherlands|Spain|Sweden|Switzerland|United Kingdom | 1 |
| United States|Australia|Austria|Canada|Croatia|Czechia|Finland|France|Germany|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Portugal|Romania|Serbia|Singapore|Spain|Taiwan|Turkey|United Kingdom | 1 |
| United States|Australia|Austria|Canada|France|Germany|Italy|Japan|Netherlands|Norway | 1 |
| United States|Australia|Austria|Czechia|France|Italy|Spain|Sweden|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Czechia|France|Italy|Korea, Republic of|Poland|Spain|United Kingdom | 1 |
| United States|Australia|Belgium|Czechia|Finland|Germany|Israel|Sweden|Switzerland|United Kingdom | 1 |
| United States|Australia|Belgium|Italy|Korea, Republic of|Poland|Spain|United Kingdom | 1 |
| United States|Australia|Canada|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Spain|Turkey|United Kingdom | 1 |
| United States|Australia|Denmark|Spain | 1 |
| United States|Australia|France|Germany|Italy|Japan|Spain | 1 |
| United States|Australia|France|Germany|Netherlands|Spain | 1 |
| United States|Australia|France|Italy|Japan | 1 |
| United States|Australia|France|Poland|United Kingdom | 1 |
| United States|Australia|Israel|Italy|Korea, Republic of|Poland|Slovakia|Spain|United Kingdom | 1 |
| United States|Austria|Belgium|Bulgaria|Czechia|Denmark|France|Germany|Hungary|Italy|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine|United Kingdom | 1 |
| United States|Austria|Belgium|Czechia|Germany|Portugal | 1 |
| United States|Austria|Canada|Germany | 1 |
| United States|Austria|Denmark|Estonia|United Kingdom | 1 |
| United States|Belgium|Bulgaria|Czechia|Hungary|Italy|Poland|Switzerland|Ukraine | 1 |
| United States|Belgium|Canada|Germany|Korea, Republic of | 1 |
| United States|Belgium|Canada|Spain | 1 |
| United States|Belgium|Czechia|France|Germany|Hungary|Italy|Poland|Spain|United Kingdom | 1 |
| United States|Belgium|Czechia|Israel|Italy|Poland|Spain|Turkey|United Kingdom | 1 |
| United States|Belgium|France|Germany|Italy|Korea, Republic of|Spain|Turkey | 1 |
| United States|Belgium|France|Italy | 1 |
| United States|Belgium|France|Italy|Spain | 1 |
| United States|Belgium|Germany|United Kingdom | 1 |
| United States|Canada|Czechia|France|Germany|Hungary|Israel|Poland|Russian Federation|Spain|Turkey | 1 |
| United States|Canada|France|Germany|Hong Kong|Italy|Japan|Singapore|Spain | 1 |
| United States|Canada|France|Germany|Israel|Netherlands | 1 |
| United States|Canada|France|Germany|Italy | 1 |
| United States|Canada|France|Germany|Italy|Netherlands | 1 |
| United States|Canada|France|Germany|Spain|United Kingdom | 1 |
| United States|Canada|France|Italy | 1 |
| United States|Canada|Georgia|Moldova, Republic of|Poland|Spain|Ukraine | 1 |
| United States|Canada|Germany | 1 |
| United States|China | 1 |
| United States|Denmark | 1 |
| United States|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Taiwan | 1 |
| United States|France|Germany|Italy|United Kingdom | 1 |
| United States|France|Ireland|United Kingdom | 1 |
| United States|France|Korea, Republic of | 1 |
| United States|France|Spain|United Kingdom | 1 |
| United States|Germany|Ireland|Spain|United Kingdom | 1 |
| United States|Germany|Italy|Spain|United Kingdom | 1 |
| United States|Germany|Poland | 1 |
| United States|India|Israel | 1 |
| United States|Israel|Poland|Spain | 1 |
| United States|Italy|Russian Federation|Spain | 1 |
| United States|Italy|Spain|United Kingdom | 1 |
| United States|Italy|Switzerland|United Kingdom | 1 |
| United States|Italy|United Kingdom | 1 |
| United States|Saudi Arabia | 1 |
| United States|Spain|United Kingdom | 1 |
| United States|Switzerland | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 259 |
| 2 | 36 |
| 3 | 23 |
| 4 | 14 |
| 5 | 20 |
| 6 | 15 |
| 7 | 10 |
| 8 | 7 |
| 9 | 10 |
| 10 | 14 |
| 11 | 20 |
| 12 | 5 |
| 13 | 6 |
| 14 | 10 |
| 15 | 7 |
| 16 | 6 |
| 17 | 5 |
| 18 | 3 |
| 19 | 6 |
| 20 | 5 |
| 21 | 5 |
| 22 | 3 |
| 23 | 3 |
| 24 | 2 |
| 25 | 6 |
| 27 | 3 |
| 28 | 4 |
| 29 | 1 |
| 30 | 3 |
| 31 | 1 |
| 32 | 1 |
| 33 | 2 |
| 34 | 1 |
| 35 | 2 |
| 36 | 2 |
| 37 | 1 |
| 38 | 2 |
| 40 | 3 |
| 41 | 3 |
| 42 | 2 |
| 43 | 1 |
| 46 | 2 |
| 48 | 1 |
| 51 | 1 |
| 52 | 1 |
| 53 | 1 |
| 57 | 2 |
| 62 | 2 |
| 67 | 1 |
| 70 | 1 |
| 75 | 1 |
| 77 | 1 |
| 83 | 2 |
| 84 | 1 |
| 85 | 1 |
| 87 | 1 |
| 97 | 1 |
| 109 | 1 |
| 123 | 1 |
| 131 | 2 |
| 150 | 1 |
| 151 | 1 |
| 157 | 1 |
| 158 | 1 |
| 162 | 1 |
| 164 | 1 |
| 173 | 1 |
| 186 | 1 |
| 190 | 1 |
| 202 | 1 |
| 206 | 1 |
| 240 | 1 |
| 246 | 1 |
| 257 | 1 |
| 273 | 1 |
| 282 | 1 |
| 510 | 1 |
| 551 | 1 |
| Phase | Study_Count |
|---|---|
| Phase 2 | 220 |
| Phase 1 | 164 |
| Phase 1/Phase 2 | 93 |
| Phase 3 | 50 |
| N/A | 30 |
| Phase 2/Phase 3 | 7 |
| Early Phase 1 | 6 |
| Phase 4 | 4 |
| Number_of_Arms | Count_of_Studies |
|---|---|
| 1 | 360 |
| 2 | 118 |
| 3 | 35 |
| 4 | 18 |
| 5 | 6 |
| 6 | 5 |
| 7 | 3 |
| 8 | 3 |
| 10 | 2 |
| 12 | 1 |
| 13 | 1 |
| 21 | 1 |
| NA | 21 |
| Measure | Early.Phase.1 | N.A | Phase.1 | Phase.1.Phase.2 | Phase.2 | Phase.2.Phase.3 | Phase.3 | Phase.4 |
|---|---|---|---|---|---|---|---|---|
| Min. | 4.00000 | 5.0 | 2.00000 | 1.00000 | 5.00000 | 108.0000 | 29.00 | 32.0 |
| 1st Qu. | 9.00000 | 42.5 | 23.50000 | 30.00000 | 36.75000 | 205.5000 | 208.50 | 45.5 |
| Median | 15.00000 | 77.0 | 38.00000 | 49.00000 | 60.00000 | 316.0000 | 307.00 | 55.0 |
| Mean | 17.33333 | 132.3 | 58.09202 | 78.88172 | 74.58636 | 365.5714 | 402.64 | 108.0 |
| 3rd Qu. | 26.25000 | 159.0 | 69.50000 | 102.00000 | 94.00000 | 412.0000 | 571.50 | 117.5 |
| Max. | 33.00000 | 713.0 | 314.00000 | 422.00000 | 348.00000 | 900.0000 | 1337.00 | 290.0 |
| group_type | Group_Count |
|---|---|
| Experimental | 836 |
| Active Comparator | 80 |
| NA | 21 |
| Other | 12 |
| Placebo Comparator | 8 |
| No Intervention | 7 |
| Sham Comparator | 1 |
| intervention_model | Study_Count |
|---|---|
| Single Group Assignment | 385 |
| Parallel Assignment | 150 |
| Sequential Assignment | 29 |
| Factorial Assignment | 4 |
| NA | 4 |
| Crossover Assignment | 2 |
| primary_purpose | Study_Count |
|---|---|
| Treatment | 538 |
| Supportive Care | 12 |
| Diagnostic | 11 |
| Prevention | 7 |
| Basic Science | 3 |
| Health Services Research | 1 |
| Other | 1 |
| NA | 1 |
| Country | Study_Count |
|---|---|
| Korea, Republic of | 7 |
| France | 6 |
| United States | 5 |
| Italy | 4 |
| NA | 4 |
| China | 2 |
| United Kingdom | 2 |
| China|Korea, Republic of|Malaysia|Singapore | 1 |
| Denmark | 1 |
| Japan | 1 |
| Serbia | 1 |
| Spain | 1 |
| United States|Canada | 1 |
| United States|France|Italy|Spain | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 20 |
| 2 | 4 |
| 4 | 2 |
| 5 | 1 |
| 9 | 1 |
| 12 | 1 |
| 15 | 1 |
| 17 | 1 |
| 24 | 1 |
| 55 | 1 |
| 56 | 1 |
| 57 | 1 |
| 107 | 1 |
| 111 | 1 |
| Measure | Observational |
|---|---|
| Min | 8.0000 |
| 1st Qu | 100.0000 |
| Median | 153.0000 |
| Mean | 342.2973 |
| 3rd Qu | 314.0000 |
| Max | 3000.0000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 18 |
| Case-Only | 7 |
| Other | 6 |
| Case Control | 2 |
| NA | 2 |
| Case-Control | 1 |
| Case-Crossover | 1 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 18 |
| Retrospective | 14 |
| Cross-Sectional | 4 |
| NA | 1 |
| Country | Study_Count |
|---|---|
| China | 1 |
| Denmark | 1 |
| Korea, Republic of | 1 |
| Spain | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 2 |
| 14 | 1 |
| 24 | 1 |
| Measure | Registries |
|---|---|
| Min | 75.00 |
| 1st Qu | 168.75 |
| Median | 600.00 |
| Mean | 818.75 |
| 3rd Qu | 1250.00 |
| Max | 2000.00 |
| observational_model | Study_Count |
|---|---|
| Cohort | 3 |
| Case-Only | 1 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 4 |
| target_duration | Study_Count |
|---|---|
| 2 Years | 2 |
| 10 Years | 1 |
| 36 Months | 1 |
#If less then 500 trials
#If less then 500 studies
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT03378947 | EBV-associated Diffuse Large B Cell Lymphoma | https://ClinicalTrials.gov/show/NCT03378947 | Completed | Hospices Civils de Lyon | 2018-01-15 |
| NCT03226704 | Leukapheresis for CAR-Therapy Manufacturing | https://ClinicalTrials.gov/show/NCT03226704 | Recruiting | National Institutes of Health Clinical Center (CC) | 2023-05-01 |
| NCT03211702 | Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2) | https://ClinicalTrials.gov/show/NCT03211702 | Active, not recruiting | Chonbuk National University Hospital | 2018-04-30 |
| NCT03104478 | Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL) | https://ClinicalTrials.gov/show/NCT03104478 | Recruiting | The Lymphoma Academic Research Organisation | 2020-12-31 |
| NCT03042247 | Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma | https://ClinicalTrials.gov/show/NCT03042247 | Recruiting | Federico II University | 2020-06-10 |
| NCT03000192 | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | https://ClinicalTrials.gov/show/NCT03000192 | Active, not recruiting | University Hospital Southampton NHS Foundation Trust | 2020-12-31 |
| NCT02885623 | Role of CX3CR1-expressing Cells in Hematologic Malignancy | https://ClinicalTrials.gov/show/NCT02885623 | Recruiting | Saint Vincent’s Hospital, Korea | 2019-08-31 |
| NCT02708732 | Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL) | https://ClinicalTrials.gov/show/NCT02708732 | Completed | Hoffmann-La Roche | 2016-10-31 |
| NCT02555267 | Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma | https://ClinicalTrials.gov/show/NCT02555267 | Active, not recruiting | Chonbuk National University Hospital | 2017-07-31 |
| NCT02486952 | MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma | https://ClinicalTrials.gov/show/NCT02486952 | Completed | Hoffmann-La Roche | 2011-01-31 |
| NCT02364050 | Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM | https://ClinicalTrials.gov/show/NCT02364050 | Active, not recruiting | Fondazione Italiana Linfomi ONLUS | 2017-12-31 |
| NCT02060435 | Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma | https://ClinicalTrials.gov/show/NCT02060435 | Completed | Samsung Medical Center | 2013-12-31 |
| NCT01311232 | Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab | https://ClinicalTrials.gov/show/NCT01311232 | Completed | Samsung Medical Center | 2012-12-01 |
| NCT01793233 | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | https://ClinicalTrials.gov/show/NCT01793233 | Active, not recruiting | Children’s Oncology Group | 2020-12-31 |
| NCT01660776 | BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology | https://ClinicalTrials.gov/show/NCT01660776 | Completed | Rennes University Hospital | 2017-10-02 |
| NCT01606605 | Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma | https://ClinicalTrials.gov/show/NCT01606605 | Completed | Samsung Medical Center | 2012-12-31 |
| NCT01563861 | S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma | https://ClinicalTrials.gov/show/NCT01563861 | Completed | Southwest Oncology Group | 2008-06-01 |
| NCT01483664 | Communication Skills Intervention to Promote Transition Into Survivorship | https://ClinicalTrials.gov/show/NCT01483664 | Active, not recruiting | Memorial Sloan Kettering Cancer Center | 2020-11-30 |
| NCT01369784 | Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma | https://ClinicalTrials.gov/show/NCT01369784 | Completed | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2011-03-31 |
| NCT01340443 | An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | https://ClinicalTrials.gov/show/NCT01340443 | Completed | Hoffmann-La Roche | 2016-07-15 |
| NCT04423549 | Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma | https://ClinicalTrials.gov/show/NCT04423549 | Recruiting | Sun Yat-sen University | 2021-06-30 |
| NCT04354402 | Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL | https://ClinicalTrials.gov/show/NCT04354402 | Enrolling by invitation | SymBio Pharmaceuticals | 2020-12-31 |
| NCT04319237 | Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes | https://ClinicalTrials.gov/show/NCT04319237 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 2022-06-30 |
| NCT04317313 | Prediction of Outcome Using Pretreatment 18F-FDG PET/CT Radiomic Features in Diffuse Large B-cell Lymphoma | https://ClinicalTrials.gov/show/NCT04317313 | Completed | Second Affiliated Hospital, School of Medicine, Zhejiang University | 2018-09-30 |
| NCT04183569 | Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma | https://ClinicalTrials.gov/show/NCT04183569 | Active, not recruiting | University Hospital, Bordeaux | 2020-05-01 |
| NCT04150328 | Lenalidomide Monotherapy in R/R DLBCL | https://ClinicalTrials.gov/show/NCT04150328 | Recruiting | MorphoSys AG | 2019-08-29 |
| NCT03977623 | Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression | https://ClinicalTrials.gov/show/NCT03977623 | Recruiting | Samsung Medical Center | 2022-02-28 |
| NCT03797170 | Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma | https://ClinicalTrials.gov/show/NCT03797170 | Recruiting | University of Bologna | 2020-07-20 |
| NCT03664336 | Refractory Diffuse Large B-cell Lymphoma | https://ClinicalTrials.gov/show/NCT03664336 | Completed | Hospices Civils de Lyon | 2017-07-31 |
| NCT01266668 | The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL) | https://ClinicalTrials.gov/show/NCT01266668 | Completed | Chonbuk National University Hospital | 2011-05-31 |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | https://ClinicalTrials.gov/show/NCT01199562 | Completed | City of Hope Medical Center | 2013-12-31 |
| NCT01131208 | Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab | https://ClinicalTrials.gov/show/NCT01131208 | Completed | Eastern Cooperative Oncology Group | 2010-08-21 |
| NCT00949741 | Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin’s Lymphoma Patients | https://ClinicalTrials.gov/show/NCT00949741 | Completed | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | 2011-10-31 |
| NCT00898157 | Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494 | https://ClinicalTrials.gov/show/NCT00898157 | Completed | Eastern Cooperative Oncology Group | 2008-09-24 |
| NCT00822432 | Coproporphyrine Isomers and Methotrexate Elimination | https://ClinicalTrials.gov/show/NCT00822432 | Completed | Assistance Publique - Hôpitaux de Paris | 2011-08-31 |
| NCT00754117 | Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET) | https://ClinicalTrials.gov/show/NCT00754117 | Completed | Weill Medical College of Cornell University | 2010-12-31 |
| NCT00286832 | Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV | https://ClinicalTrials.gov/show/NCT00286832 | Completed | Copenhagen University Hospital at Herlev | 2011-01-31 |
#If less then 500 registries
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT02474550 | Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma | https://ClinicalTrials.gov/show/NCT02474550 | Recruiting | Ajou University School of Medicine | 2018-12-31 |
| NCT04112238 | ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma | https://ClinicalTrials.gov/show/NCT04112238 | Recruiting | Herlev Hospital | 2023-06-30 |
| NCT03715296 | Lenalidomide Based Immunotherapy in the Treatment of DLBCL | https://ClinicalTrials.gov/show/NCT03715296 | Recruiting | Ruijin Hospital | 2020-09-15 |
| NCT03646422 | AEDV Registry of Primary Cutaneous Lymphoma | https://ClinicalTrials.gov/show/NCT03646422 | Recruiting | Fundación Academia Española de DermatologÃa | 2025-01-01 |